Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report

M&A will help the biopharma industry deal with significant new challenges, Morningstar said in a new report, including pressure from lawmakers and payers to lower prices. As companies look for deals to boost their pipelines, oncology, neurology and rare-disease therapeutics will emerge as sought-after assets, the analysts predicted.